honokiol has been researched along with Cirrhosis, Liver in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, CH; Cho, AR; Kim, B; Kim, SH; Koo, J; Lee, HJ; Park, JE; Park, SY; Seo, JH; Shim, BS; Sim, DY | 1 |
| El-Demerdash, E; Elfeky, MG; Fawzy, HM; Gad, AM; Mantawy, EM | 1 |
| Im, E; Jung, JH; Kim, SH; Lee, HJ; Lee, IH; Lee, JH; Park, JE; Shim, BS; Sim, DY | 1 |
3 other study(ies) available for honokiol and Cirrhosis, Liver
| Article | Year |
|---|---|
Honokiol inhibits epithelial-mesenchymal transition and hepatic fibrosis via activation of Ecadherin/GSK3β/JNK and inhibition of AKT/ERK/p38/β-catenin/TMPRSS4 signaling axis.
Topics: Animals; beta Catenin; Cadherins; Catenins; Epithelial-Mesenchymal Transition; Fibrinolytic Agents; Glycogen Synthase Kinase 3 beta; Leukemia, Myeloid, Acute; Liver Cirrhosis; Mice; Proto-Oncogene Proteins c-akt; Transforming Growth Factor beta1 | 2023 |
Mechanistic aspects of antifibrotic effects of honokiol in Con A-induced liver fibrosis in rats: Emphasis on TGF-β/SMAD/MAPK signaling pathways.
Topics: Actins; Animals; Biphenyl Compounds; Concanavalin A; Hydroxyproline; Inflammation; Lignans; Liver Cirrhosis; Male; Mitogen-Activated Protein Kinases; Oxidative Stress; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Survival Analysis; Transforming Growth Factor beta | 2020 |
Apoptotic and antihepatofibrotic effect of honokiol via activation of GSK3β and suppression of Wnt/β-catenin pathway in hepatic stellate cells.
Topics: Actins; beta Catenin; Biphenyl Compounds; Caspase 3; Cell Line; Cyclin D1; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Hepatic Stellate Cells; Humans; Lignans; Liver Cirrhosis; Phosphorylation; Smad3 Protein; Transforming Growth Factor beta1; Wnt Signaling Pathway | 2021 |